ATRS earnings call for the period ending March 31, 2019.
News & Analysis: Antares Pharma
ATRS earnings call for the period ending December 31, 2018.
An FDA approval for its testosterone drug has investors hitting the buy button.
Get the scoop on the latest in M&A land.
A deal with Pfizer has investors smiling, but there's no way to analyze the value to the company.
Favorable regulatory news causes traders to cheer.
An FDA rejection is coming for the drugmaker's testosterone replacement therapy Xyosted.
Antares Pharma, Inc. shares tumbled after it priced its secondary stock offering.
Find out which health-care stocks got beaten down the most by the market over the past few days.
Antares shares go off track following the resignation of its CEO. Find out if this is something investors should be genuinely concerned about or if it's a short-term event.